AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00400114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
Study NCT00400114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
Study NCT00400114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation 50 Gy (weeks 4-9)
Study NCT00400114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Esophagectomy
Study NCT00400114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib (Sutent)
Description: sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
Study NCT02616471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat cheese
Study NCT02616471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-fat cheese
Study NCT02616471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No-cheese/carbohydrate
Study NCT02393586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: Single oral dose
Study NCT02393586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 500mg/125mg
Description: Single oral dose
Study NCT02393586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose
Study NCT05155462 — intervention group
Intervention type: OTHER
Intervention: One or two phone call
Description: Phone call to collect patient data
Study NCT03867409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message delivered via virtual technology
Description: The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
Study NCT03217981 — intervention group
Intervention type: OTHER
Intervention: Sepsis protocol
Description: Adherence to the sepsis protocol
Study NCT01371370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
Study NCT01371370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
Study NCT01371370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training & diet
Description: Combination of low intensity resistance exercise training and hypocaloric diet
Study NCT02764125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stalevo
Description: levodopa/carbidopa/entacapone
Study NCT04123873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g x 4 p.o.
Study NCT04123873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg x 4 p.o.
Study NCT04210245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for aldafermin
Study NCT04123873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 24mg IV x 1 after induction om anaesthesia
Study NCT04123873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsules
Description: p.o. x 4
Study NCT04123873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: IV x 1
Study NCT03528135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project PRIDE
Description: See arms section.
Study NCT00977028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent Local Anesthesia (lidocaine, epinephrine)
Description: Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
Study NCT00977028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
Study NCT03247062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality improvement - sleep bundle
Description: implementation of a sleep bundle
Study NCT02635061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: Specified dose on specified days
Study NCT02635061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02034721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: 24 g protein before, 12 g during, and 24 g after eccentric exercise
Study NCT02034721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04091438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-925
Description: TAK-925 IV infusion.
Study NCT04091438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 IV infusion.
Study NCT04091438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching IV infusion.
Study NCT04091438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching IV infusion.
Study NCT02445885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Guideline directed Percutaneous Coronary Intervention
Study NCT02445885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Guideline directed Percutaneous Coronary Intervention
Study NCT00647348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80mg simvastatin oral once daily for 24 months
Study NCT00647348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet once daily for 24 months
Study NCT02783963 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT and CMR imaging
Description: OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.
Study NCT01385995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)
Description: Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
Study NCT01385995 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)
Description: Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Low Molecular Weight (20-200 Mpa.S)
Description: deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Diacetate
Description: Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
Study NCT04365270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titanium Dioxide
Description: Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), >99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
Study NCT02976688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
Study NCT04190771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment NAT-FM
Description: Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT04190771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT04190771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study NCT01126398 — intervention group
Intervention type: PROCEDURE
Intervention: ankle or distal tibia surgery
Description: internal fixation for ankle or distal tibia fracture
Study NCT01561612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion and support
Description: Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
Study NCT04431284 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
Study NCT03505424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Standard of Care
Description: Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team.
Study NCT03705104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EPIO
Description: App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
Study NCT04555655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken extract supplement
Description: 70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
Study NCT03505424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: NICU2HOME app
Description: In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
Study NCT03505424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: SMART NICU2HOME app
Description: In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
Study NCT03422731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow and blood samples
Study NCT03422731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow and blood samples
Study NCT03422731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo DECT
Study NCT03422731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT PET
Study NCT03422731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03422731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03422731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo water-fat MRI
Study NCT03422731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FLT PET
Study NCT04555655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptide Supplement
Description: 70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
Study NCT04555655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
Study NCT02405039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005
Description: EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
Study NCT02405039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1.0-1.5 g oral dose twice daily
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil [CellCept]
Description: 1.0-1.5 g oral dose twice daily
Study NCT06689111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing lead
Description: Use of LBBp Vs the standard method of BiVp in resynchronization therapy
Study NCT06689111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT with the standard method through cs
Description: standard CRT procedure
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: As prescribed
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors
Description: As prescribed
Study NCT00121810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: As prescribed
Study NCT04222127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EUS guided injection of gastric varices by CYA
Description: EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
Study NCT04222127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct endoscopic injection of gastric varices by CYA
Description: Direct endoscopic injection of gastric varix by CYA
Study NCT02481518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
Study NCT02481518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
Study NCT04292119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days.
Study NCT04292119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days.
Study NCT04292119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be taken orally twice daily for 28 days.
Study NCT04292119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: TNO155 will be taken orally once daily for 14 days.
Study NCT02747043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 798
Description: ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
Study NCT02747043 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
Study NCT02237053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Study NCT01398761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Signout tool
Description: Electronic signout tool
Study NCT06685939 — intervention group
Intervention type: PROCEDURE
Intervention: LPD
Description: The patients who received the LPD
Study NCT03431805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
Study NCT03431805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
Study NCT02150044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery System (TTDS).
Description: tympanostomy tube delivery system
Study NCT02015533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR8020
Description: CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
Study NCT02764125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa MR
Description: levodopa MR/carbidopa/ODM-104
Study NCT03895242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1:Supine-Prone
Description: After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.